0001437749-22-006207.txt : 20220314
0001437749-22-006207.hdr.sgml : 20220314
20220314195852
ACCESSION NUMBER: 0001437749-22-006207
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220303
FILED AS OF DATE: 20220314
DATE AS OF CHANGE: 20220314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AUERBACH ALAN H
CENTRAL INDEX KEY: 0001358285
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35703
FILM NUMBER: 22738427
MAIL ADDRESS:
STREET 1: 10940 WILSHIRE BLVD. SUITE 600
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PUMA BIOTECHNOLOGY, INC.
CENTRAL INDEX KEY: 0001401667
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770683487
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
BUSINESS PHONE: (424) 248-6500
MAIL ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
FORMER COMPANY:
FORMER CONFORMED NAME: INNOVATIVE ACQUISITIONS CORP
DATE OF NAME CHANGE: 20070601
4
1
rdgdoc.xml
FORM 4
X0306
4
2022-03-03
0001401667
PUMA BIOTECHNOLOGY, INC.
PBYI
0001358285
AUERBACH ALAN H
C/O PUMA BIOTECHNOLOGY, INC.
10880 WILSHIRE BLVD., SUITE 2150
LOS ANGELES
CA
90024
1
1
1
President and CEO
Common Stock
2022-03-03
4
A
0
168824
0
A
4555639
D
Common Stock
2022-03-10
4
A
0
1792114
2.79
A
6347753
D
Stock Option (Right to Buy)
2.33
2022-03-03
4
A
0
241176
0
A
2032-03-02
Common Stock
241176
241176
D
Subject to the Grantee's continued status as an Employee, the Restricted Stock Units shall vest with respect to one-fourth (1/4th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024, subject to acceleration in certain events.
On March 8, 2022, the Issuer entered into a Securities Purchase Agreement with certain purchasers, including the Reporting Person. Shares were purchased at $2.79 per share and issued at closing on March 10, 2022.
Subject to the Optionee's continued status as an Employee, the Option shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares (as defined in the Plan) subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024, subject to acceleration in certain events.
/s/ Alan H. Auerbach
2022-03-14